Ocugen reports 31% reduction in GA lesion growth at 12 months in Phase 2 OCU410 trial; plans Phase 3 in Q3 2026

Ocugen, Inc.

31% reduction in GA lesion growth (medium dose) vs control at 12 months (p<0.05); 55% of treated patients had ≥30% lesion reduction.
No OCU410-related serious adverse events; no endophthalmitis, retinal detachment, or vasculitis reported.
27% slower rate of ellipsoid zone loss vs control, indicating photoreceptor preservation.
Phase 3 pivotal trial with up to 300 subjects, adaptive design >95% power, expected to start Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.